Alpelisib (phosphatidylinositol 3-kinase inhibitor) induced uncontrolled hyperglycemia and colitis
Alpelisib is currently the only Phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treating endocrine therapy-resistant metastatic breast cancer with a Phosphatidylinositol-4,5-bisphosphonate 3-kinase catalytic subunit alpha (PIK3CA)-mutation. Significant side effects of treatment include h...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2024-06-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Assuntos: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S2666621924000176 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|